Overview

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The aim is to evaluate efficacy and safety of three different dosing regimens of Limtop in a study involving 96 patients with actinic keratosis on the head or face.

Phase:

Phase 2

Details

Lead Sponsor:

Moberg Pharma AB

Treatments:

Imiquimod